Evaluating Travoprost Implant for Glaucoma
This study is testing a new implant called Gen 2 Travoprost Intracameral Implant for people with glaucoma or ocular hypertension (high pressure in the eye). Researchers want to see how safe and effective this implant is compared to Timolol eye drops 0.5%. You might receive the Travoprost implant, Timolol eye drops, a sham procedure (a fake implant administration), or placebo eye drops (artificial tears). The main goal is to measure your eye pressure after 3 months to see if the implant works. To join, you must be at least 18 years old and have open-angle glaucoma or ocular hypertension in the eye being studied. You cannot have had certain eye surgeries before. The study plans to enroll 610 people, but its current status is unclear.
- Study design
- This is an interventional study comparing different treatments for glaucoma. It plans to enroll 610 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your eye pressure will be measured at 3 months after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
At a glance
Conditions
Where it's being run
3 sites across 3 statesStudy leadership
- Luis G. Vargas, MD · STUDY_CHAIR · Glaukos Corporation
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Intraocular pressure (IOP)3 months
Change from baseline in diurnal IOP in the study eye at 8AM and 10AM at each of Day 11, Week 6, and Month 3 visits